GlassScriptPhysician profile
Sandra Yu Kim
NPI 1306355698
$3,329.25
in general payments reported to CMS, 2019-2025
18 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $420 · 2022: $697 · 2023: $424 · 2024: $707 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $651.55 | 2022-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $449.68 | 2022 | |
| Amgen INC. | $443.67 | 2024-2025 | Evenity, Prolia |
| Lilly USA, LLC | $416.12 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $318.24 | 2023-2025 | |
| Abbvie INC. | $270.94 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $149.29 | 2023-2025 | Jynarque |
| Teva Pharmaceuticals USA, INC. | $120.79 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.22 | 2021 | |
| Biogen, INC. | $95.81 | 2021 | |
| Merck Sharp & Dohme LLC | $80.61 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Electromed, INC. | $67.90 | 2024-2025 | Smartvest |
| Glaxosmithkline, LLC. | $46.47 | 2023 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $32.43 | 2025 | Farxiga |
| Abiomed | $27.82 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.37 | 2025 | |
| Lundbeck LLC | $18.05 | 2025 | Rexulti |
| Exact Sciences Corporation | $17.29 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.